Navigation Links
Novel export-inhibitor shows promise for treating CLL
Date:12/12/2011

An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The agent, called KPT-SINE, belongs to a new class of drugs called selective inhibitors of nuclear export (SINE). The agent was developed by Karyopharm Therapeutics Inc. It is designed to kill cancer cells by restoring biochemical pathways that normally cause unhealthy cells to self-destruct through a process called programmed cell death, or apoptosis.

The agent targets a protein called CRM1, which, until now, has not been adequately explored in CLL, the researchers say. During disease progression, cancer cells use CRM1 to shunt certain apoptosis-related proteins out of the nucleus, thereby avoiding cell death.

"We believe that KPT-SINE and other nuclear-export inhibitors may represent a unique, entirely new therapeutic strategy for treating cancer by simultaneously restoring multiple normal cell death pathways," says OSUCCC James research scientist Dr. Rosa Lapalombella who is a co-investigator on the study with Dr. John Byrd, director of the division of hematology and co-director of the OSUCCC James CLL Experimental Therapeutics Laboratory at OSUCCC James.

The researchers hypothesize that KPT-SINE will inhibit CRM1 and keep these regulatory proteins in the nucleus where they can initiate programmed cell death.

Lapalombella will discuss the role of CRM1 inhibition in the treatment of CLL on Monday, December 12, at 7:00 a.m. during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

The study, which used CLL cells from patients and a mouse model of CLL, provides essential proof-of-concept data to design and initiate phase I clinical testing of KPT-SINE in patients with these incurable diseases, Lapalombella notes.

"We are excited by our preliminary findings that KPT-SINE represents a promising targeted therapy for CLL patients," Byrd says. "We look forward to transitioning our research toward early clinical development in patients with CLL and related diseases, based upon the data generated by our team."
'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Novel experimental agent is highly active in CLL patients, interim study shows
2. Researchers identify a novel therapeutic approach for liver cancer
3. Novel drug wipes out deadliest malaria parasite through starvation
4. Novel approach to treating breast cancer shows great promise
5. Wayne State receives $1.9 million from NIH to create novel cystic fibrosis treatments
6. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
7. Wayne State University to study novel treatment for antibiotic-resistant bacteria
8. Novel, noninvasive measurement a strong predictor for heart failure in general population
9. UK HealthCare surgeons are first to perform novel procedures prior to transplant
10. Novel approach to treat proliferative vitreoretinopathy shows promise
11. Novel strategy stymies SARS et al.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of a growth round of funding led by Eastside Partners, with participation from ... company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
(Date:4/29/2016)... ... 29, 2016 , ... Intellitec Solutions is pleased to announce ... GP for one their long-term care clients. Working together with the clients staff, ... clinical management systems, and delivered a fully integrated accounting and business-management solution that ...
(Date:4/29/2016)... ... 2016 , ... The number of chronically and seriously ill individuals is growing. ... an urgent need for highly skilled care managers and care coordinators. Care ... train and retain care managers, and enhance their skills. , Care Excellence ...
(Date:4/28/2016)... ... 2016 , ... The Dentists Insurance Company (TDIC), ... letter of intent with Moda to acquire Dentists Benefits Insurance Company ... by dentists 36 years ago, TDIC focuses exclusively on supporting the dental profession ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... 27 Avril 2016   ... de +5% sur le trimestre, soutenu par une ... Croissance de +16% des ventes aux ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), ... annonce aujourd,hui son chiffre d,affaires pour le premier ...
Breaking Medicine Technology: